News
BOLT
4.700
+0.64%
0.030
Weekly Report: what happened at BOLT last week (0504-0508)?
Weekly Report · 14h ago
Weekly Report: what happened at BOLT last week (0427-0501)?
Weekly Report · 05/04 09:29
Bolt Biotherapeutics announces annual shareholder meeting
PUBT · 04/28 20:09
Weekly Report: what happened at BOLT last week (0420-0424)?
Weekly Report · 04/27 09:30
Weekly Report: what happened at BOLT last week (0413-0417)?
Weekly Report · 04/20 09:28
Weekly Report: what happened at BOLT last week (0406-0410)?
Weekly Report · 04/13 09:30
JonesTrading Keeps Their Hold Rating on Bolt Biotherapeutics (BOLT)
TipRanks · 04/07 08:56
Weekly Report: what happened at BOLT last week (0330-0403)?
Weekly Report · 04/06 09:30
Weekly Report: what happened at BOLT last week (0323-0327)?
Weekly Report · 03/30 09:30
Weekly Report: what happened at BOLT last week (0316-0320)?
Weekly Report · 03/23 09:29
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/17 08:50
Weekly Report: what happened at BOLT last week (0309-0313)?
Weekly Report · 03/16 09:28
Buy Rating on Bolt Biotherapeutics Driven by Differentiated Claudin 18.2 ISAC BDC-4182 and Solid Cash Runway to 2027
TipRanks · 03/13 10:25
Bolt Biotherapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/13 10:20
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
Benzinga · 03/13 10:12
Bolt Biotherapeutics Q4 loss narrows as expenses fall
Reuters · 03/12 20:58
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
TipRanks · 03/12 20:31
Bolt Biotherapeutics Q4 operating loss narrows 58% to USD 7.1 million on R&D expenses down 57% to USD 5 million
Reuters · 03/12 20:16
*Bolt Biotherapeutics 4Q Loss/Shr $3.84 >BOLT
Dow Jones · 03/12 20:06
Press Release: Bolt Biotherapeutics Reports -3-
Dow Jones · 03/12 20:06
More
Webull provides a variety of real-time BOLT stock news. You can receive the latest news about Bolt Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.